Reneo Pharmaceuticals company info

What does Reneo Pharmaceuticals do?
Reneo Pharmaceuticals (NASDAQ:RPHM) focuses on developing novel therapies aimed at helping patients with genetic mitochondrial diseases, where there's a severe unmet medical need. Their work centers around enhancing mitochondrial function which is crucial for energy production in the body. Currently, Reneo Pharmaceuticals is pioneering research into REN001, a drug designed to treat conditions like primary mitochondrial myopathies, fatty acid oxidation disorders, and long-chain fatty acid oxidation disorders. Thei main objective is not just to manage but to significantly improve the quality of life for people dealing with these challenging conditions through groundbreaking scientific advancements. They are fully committed to transforming the landscape of treatment for mitochondrial diseases with their cutting-edge research and innovative approaches. This dedication underscores their mission to bring hope and new possibilities to patients and families navigating these rare and complex disorders.
Reneo Pharmaceuticals company media
Company Snapshot

Is Reneo Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Reneo Pharmaceuticals employ?

people
Employees
8

What sector is Reneo Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Reneo Pharmaceuticals?

location pin
Head Office
Irvine, United States

What year was Reneo Pharmaceuticals founded?

founded flag
Year Founded
2014
What does Reneo Pharmaceuticals specialise in?
/Rare Diseases /Drug Development /Fatty Acid Oxidation /Pharmaceutical Research /Clinical Trials /Therapeutic Solutions

What are the products and/or services of Reneo Pharmaceuticals?

Overview of Reneo Pharmaceuticals offerings
Development of REN001, a treatment aimed at rare genetic mitochondrial diseases for improving muscle and liver function.
Clinical trials for REN001 in primary mitochondrial myopathies to enhance physical capabilities and reduce fatigue.
Expansion of REN001 studies to include patients with fatty acid oxidation disorders, offering potential treatment for energy production issues.
Investigation into the effectiveness of REN001 for people suffering from long-chain fatty acid oxidation disorders, addressing energy deficiency.
Collaborations with research institutions for the advancement of mitochondrial and metabolic disease understanding.
Efforts in patient advocacy and education to support individuals living with mitochondrial diseases through information and resource sharing.

Who is in the executive team of Reneo Pharmaceuticals?

Reneo Pharmaceuticals leadership team
  • Mr. Michael G. Grey
    Mr. Michael G. Grey
    Founder & Executive Chairman
  • Mr. Gregory J. Flesher
    Mr. Gregory J. Flesher
    President, CEO & Director
  • Mr. Michael P. Cruse
    Mr. Michael P. Cruse
    Chief Operating Officer
  • Ms. Ashley F. Hall J.D.
    Ms. Ashley F. Hall J.D.
    Chief Development Officer
  • Ms. Jennifer P. Lam
    Ms. Jennifer P. Lam
    SVP of Finance & Administration and Principal Financial & Accounting Officer
  • Dr. Alejandro  Dorenbaum M.D.
    Dr. Alejandro Dorenbaum M.D.
    Chief Medical Officer
  • Ms. Lynn  Purkins Ph.D.
    Ms. Lynn Purkins Ph.D.
    Senior Vice President of Global Development